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min, or left untreated. Then TG was added (left arrow). After the Ca 2+ efflux became stable, extracellular Ca 2+ was added (right arrow). Right panel, Fluo-4/AM-loaded HEp-2 cells were pretreated with 10 μM GSK-7975A, or left untreated. Then infected with HSV-1 (arrow). For each condition, data were obtained from three replications, each of which included 10 cells, meaning a total of 30 cells per condition [same for (B), (C), (E), and (G)]. (B) Effect of 1-oleoyl-2-acetyl-sn-glycerol (OAG)-induced Ca 2+ influx. HEp-2 cells were pretreated with 10 μM GSK-7975A for 10 min, or left untreated. Then 100 μM OAG was added (arrow). (C) Effect of TG on HSV-1-induced Ca 2+ influx. Fluo-4/AM-loaded HEp-2 cells were treated with TG (1 st arrow) before HSV-1 addition (2 nd arrow). (D) Inhibition of SOCE does not affect HSV-1 binding. Representative images of HEp-2 cells treated with 2-APB or GSK-7975A.
HSV-1 binding was assessed by immunofluorescence (nuclei stained with DAPI; green, HSV-1). (E) Effect of gD-negative HSV-1 on HSV-1-induced Ca 2+ influx. Left: gD-negative HSV-1 mutant fails to enter host cells as shown by immunofluorescence (nuclei stained with DAPI; green, HSV-1). Right, SOCE in gD-negative HSV-1-infected HEp-2 cells. SOCE was monitored as in (A). (F) Effect of siSTIM1, siOrai1, and siTRPC1 as analyzed by western blotting. Band intensities were normalized to that of loading control from the same gel. Then the results for siRNA groups were normalized to that of the scrambled siRNA and are shown as relative values (n = 3 blots for each treatment). (G) Effect of knockdown of TRPC channels in HSV-1-induced SOCE. TRPC3, C4, C5, and C6 siRNA were transfected into infected HEp-2 cells, and HSV-1-induced SOCE was monitored as in (A). *P <0.05, **P <0.01 by unpaired t-test (F and G); graphs show the mean ± SD; scale bars, 10 μm. intensities were normalized to that of loading control from the same gel. Then the results for HSV-1-infected group were normalized to that of the mock-infected control and are shown as relative values. (C) Effect of pore-dead mutant, TRPC1 D581K , on SOCE. WT TRPC1 and TRPC1 D581K -transfected HEp-2 cells were infected with 0.5 MOI of HSV-1 and then treated with TG (1 st arrow). Ca 2+ was added back to cells where indicated by the 2 nd arrow. Traces show relative fluorescence intensity. Bar graph to the right shows statistical analysis of peak fluorescence increase due to Ca 2+ influx over the resting levels. (D) TRPC1 D581K does not impair TRPC1 translocation. HSV-1 was first allowed to bind to TRPC1 D581K -or WT TRPC1-transfected HEp-2 cells, then TRPC1 translocation was visualized after exposure to HSV-1 for 0 or 15 min by TIRF microscope. Scale bar, 10m. (E) TRPC1 D581K does not impair HSV-1 entry. HEp-2 cells were transfected with WT TRPC1 and TRPC1 HSV-1 glycoproteins. Upper panels, immunoprecipitation for gB or gH-TRPC1 interaction in HSV-1-infected HEp-2 cells; lower panels, after HSV-1 entered HEp-2 cells, gD was immunoprecipitated with TRPC1, and the presence of nectin-1 in the products of immunoprecipitation was analyzed by western blot. Pre-immune IgG served as a control. Input is the whole-cell extract as a positive control. (n = 3 blots for each treatment). (B) Mutation design of TRPC1. Five mutations (sites S1 to S5) were introduced into the ectodomains of human TRPC1 alpha (total length 793 AAs). The upper AA sequence is the original sequence in the ectodomains of TRPC1, and only part of the AA sequence around the mutation sites is shown. Site mutations were introduced, and their locations are shown next to the blue arrows.
The mutated sequence is shown below. (C) Effect of TRPC1 mutants on SOCE. Five TRPC1 mutant (S1 to S5) were transfected into HEp-2 cells, and SOCE was analyzed as shown in fig.   S2A . For each condition, data were obtained from three replications, each of which included 10 cells, meaning a total of 30 cells per condition. (D) Effect of TRPC1 mutants on HSV-1 entry into CHO cells. CHO cells were transfected with mutant TRPC1 (S1-S5) and then infected with HSV-1 gL86. Entry of HSV-1 was analyzed by β-Gal assays (n = 6 for each treatment). *P <0.05, ***P <0.001 by one-way ANOVA (C) and two-way ANOVA (D). 
